Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Recurrence 2Multiple Myeloma 2Ovarian Neoplasms 1Leukemia, B-Cell 1Leukemia 1Klatskin Tumor 1Fallopian Tube Neoplasms 1Disease Progression 1Disease 1Cholangiocarcinoma 1Breast Neoplasms 1Bile Duct Neoplasms 1

Interventions

ibrutinib 3Rituximab 3Lenalidomide 3spebrutinib 2fludarabine phosphate 2Cyclophosphamide 2tirabrutinib 1ricolinostat 1pembrolizumab 1ofatumumab 1navitoclax 1idelalisib 1fludarabine 1dinaciclib 1blinatumomab 1Rabeprazole 1Magnetic Resonance Imaging 1MLN 8237 1Leukapheresis 1KW-2478 1Itraconazole 1Immunotherapy, Adoptive 1Electrocardiography 1Echocardiography 1Diphenhydramine 1Ciclopirox 1Blood Component Removal 1Biological Products 1Bendamustine Hydrochloride 1Antiemetics 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Leukemia, B-Cell × ricolinostat × Clear all
NCT02787369 2026-05-19

ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
3 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡